A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

NCT07881432 on ClinicalTrials.gov · last registry update 2026-10-19

An unusually large phase 3: 2,115 participants, more than double the 424 typical for the stage. Due to report October 2029, alongside 9 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 2,115
Started: 2026-12
Primary completion: 2029-10 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-19	First seen in registry	Registered as NOT_YET_RECRUITING, P3

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.